Publication:
Pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children receiving antiretroviral fixed-dose combination tablets while receiving rifampicin-containing tuberculosis treatment and after rifampicin discontinuation

Issued Date

2012-04-01

Resource Type

Article

ISSN

15320987
08913668

DOI

10.1097/INF.0b013e3182401c41

Other identifier(s)

2-s2.0-84858800794

Rights

Mahidol University

Rights Holder(s)

SCOPUS

Bibliographic Citation

Pediatric Infectious Disease Journal. Vol.31, No.4 (2012), 389-391

Suggested Citation

Wasana Prasitsuebsai, Tim R. Cressey, Edmund Capparelli, Nirun Vanprapar, Keswadee Lapphra, Kulkanya Chokephaibulkit Pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children receiving antiretroviral fixed-dose combination tablets while receiving rifampicin-containing tuberculosis treatment and after rifampicin discontinuation. Pediatric Infectious Disease Journal. Vol.31, No.4 (2012), 389-391. doi:10.1097/INF.0b013e3182401c41 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/14881

Research Projects

Organizational Units

Authors

Journal Issue

Thesis

Title

Pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children receiving antiretroviral fixed-dose combination tablets while receiving rifampicin-containing tuberculosis treatment and after rifampicin discontinuation

Author(s)

Wasana Prasitsuebsai
 Tim R. Cressey
 Edmund Capparelli
 Nirun Vanprapar
 Keswadee Lapphra
 Kulkanya Chokephaibulkit

Other Contributor(s)

Mahidol University
 Chiang Mai University
 Harvard School of Public Health
 University of California, San Diego

Abstract

We assessed the pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children while they were receiving nevirapine-containing fixed-dose combination tablets with rifampicin-based tuberculosis treatment and after discontinuation. The median age (range) was 9.7 (4.4-11.7) years. The nevirapine area under the concentration versus time curve from 0 to12 hours and trough concentration with rifampicin were 85.3 (40.5-170.7) mg.h/mL and 6.4 (3.00-13.27) mg/mL, respectively, providing adequate exposure. © 2012 by Lippincott Williams & Wilkins.

Keyword(s)

Medicine

Availability

URI

https://repository.li.mahidol.ac.th/handle/20.500.14594/14881

Collections

Scopus 2011-2015